Therapeutic Advances in Musculoskeletal Disease

Papers
(The H4-Index of Therapeutic Advances in Musculoskeletal Disease is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis103
Erratum to “Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feas57
The impact of psoriatic arthritis on quality of life: a systematic review33
Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients31
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review25
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers22
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis22
Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case–control study21
Systemic sclerosis associated interstitial lung disease: a survey of current practices in France20
Dispositional traits help explain individual differences in relationships between a radiographic knee osteoarthritis measure, pain, and physical function19
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib19
Early Osteoarthritis Questionnaire (EOAQ): a tool to assess knee osteoarthritis at initial stage18
A novel infrapatellar approach of ultrasound-guided intra-articular injection of the knee from both lateral and medial side: a case series18
Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1)18
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis18
Back pain treatment: a new perspective17
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment16
0.049695014953613